Phase I Trial for Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation From an HLA-Mismatched Donor (7/8) With Orca-T

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis.

Start Date01 Jan 2026

Sponsor / Collaborator

Stanford University

[+1]

NCT07216443

/ RecruitingPhase 2

A Phase 2 Trial in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome Undergoing Reduced Intensity or Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Orca-T

This study will evaluate the safety, tolerability, and efficacy of Orca-T in participants undergoing reduced intensity or non-myeloablative allogeneic hematopoietic cell transplantation (alloHCT) for hematologic malignancies. Orca-T is an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons).

Start Date01 Nov 2025

Sponsor / Collaborator

Orca Biosystems, Inc.

NCT06195891

/ RecruitingPhase 1IIT

A Single Center, Non-Randomized, Phase 1b Study of Orca-T Following Escalated Dose of Total Marrow and Lymphoid Irradiation in Patients With Acute Leukemias and MDS

This phase I trial tests the side effects and best dose of total marrow lymphoid irradiation along with chemotherapy, with fludarabine and melphalan, with or without thiotepa, in combination with Orca-T cells for patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) or myelodysplastic syndrome (MDS). Total marrow and lymphoid irradiation is a targeted form of total body irradiation that uses intensity-modulated radiation therapy to target marrow, lymph node chains, and the spleen. It is designed to reduce radiation-associated side effects and maximize the radiation therapeutic effect. Giving chemotherapy with medications such as thiotepa, fludarabine, and melphalan before a treatment with stem cells helps kill cancer cells in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. Orca-T cells take cells from a donor and remove some of the T cells and replace them with partially engineered T cells in order to induce better tolerance in patients. Giving total marrow and lymphoid irradiation and chemotherapy followed by Orca -T cells may be an effective treatment for patients with AML, ALL or MDS.

Start Date24 May 2024

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

100 Clinical Results associated with Orca-T (Orca Bio)

100 Translational Medicine associated with Orca-T (Orca Bio)

100 Patents (Medical) associated with Orca-T (Orca Bio)

Literatures (Medical) associated with Orca-T (Orca Bio)

01 Sep 2025·Clinical Lymphoma Myeloma & Leukemia

SOHO State of the Art Updates and Next Questions | Transplanting Hope: Managing Relapsed/Refractory AML

Review

Author: Waller, Edmund K ; Funk, Christopher Ronald

Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of myeloid precursor cells, with high relapse rates, particularly in patients who fail to achieve morphological remission after induction therapy. Allogeneic hematopoietic cell transplantation (allo-HCT) can induce durable remissions through the graft-versus-leukemia (GVL) effect, yet current approaches of allo-HSCT often fail, with relapse rates of ∼40% within 6 months post-transplant. Outcomes following allo-HCT are inversely proportional to leukemia burden at the time of transplant. Both morphological relapse (≥5% blasts in the marrow) or minimal residual disease (MRD) positivity predict significantly reduced overall survival rates. Emerging strategies to improve outcomes in patients with high leukemic burden include aggressive bridging therapies (encompassing intensive salvage chemotherapy, hypomethylating agents, targeted inhibitors, and sequential induction-conditioning approaches such as FLAMSA), tailored conditioning regimens, post-transplant maintenance therapy, and innovative graft engineering methods. Graft engineering strategies, such as ORCA-T, which engineers stem cell grafts with a defined ratio of T-regulatory cells to effector T cells, are particularly promising and under evaluation in phase III clinical trials. These approaches aim to improve upon the poor outcomes for patients with persistent/relapsed AML undergoing allo-HCT.

01 Oct 2022·Clinical Lymphoma Myeloma & Leukemia

CT-524 Orca-T, A Precision Engineered Allograft, Results in High GVHD-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies

Article

Author: Putnam, Amy ; Meyer, Everett ; Waller, Edmund ; Gandhi, Arpita ; Hoeg, Rasmus ; Fernhoff, Nathaniel ; Abedi, Mehrdad ; Oliai, Caspian ; Killian, M Scott ; Shaw, Bronwen ; Pavlova, Anna ; Negrin, Robert ; Mcclellan, James ; Mehta, Rohtesh ; Srour, Samer ; McGuirk, Joseph

BACKGROUND:

Rates of graft-versus-host disease (GVHD) and non-relapse mortality (NRM) following myeloablative allogeneic hematopoietic stem cell transplant (MA-alloHSCT) remain unacceptably high. Orca-T is a high-precision, allogeneic investigational cell therapy product comprised of stem and immune cells that leverages highly purified, polyclonal donor regulatory T cells to control alloreactive immune responses, reducing the need for pharmacologic GVHD prophylaxis. Orca-T is produced in a central GMP facility and has been successfully scaled to clinical centers throughout the U.S.

AIMS:

The aim of these studies was to evaluate the safety and efficacy of Orca-T in patients with hematologic malignancies.

METHODS:

Data are reported for 138 patients with high-risk hematologic malignancies who received Orca-T in a single-center Phase 1/2 study (n=41) and a multicenter Phase 1b study (n=97) and had ≥ 100 days of follow-up as of 2/28/22. Orca-T was produced from G-CSF-mobilized peripheral blood (PB) from MRD (n=72), MUD (n=62), or MMUD (n=4). Median follow-up for recipients was 300 days (range: 27-1941). Median age was 49 years, and diagnoses included AML (43%), ALL (27%), MDS (10%), myelofibrosis (7%), and CML (6%). Patients received MAC (busulfan-based, n=109; TBI-based, n=27; BCNU, n=2) followed by GVHD prophylaxis with either single-agent tacrolimus (n=127), sirolimus (n=7), or tacrolimus plus mycophenolate (n=4, MMUD). A contemporaneous CIBMTR-based control arm was obtained that consisted of patients with similar diagnoses who received MA-alloHSCT from a PB source followed by tacrolimus/methotrexate prophylaxis.

RESULTS:

Orca-T was successfully manufactured, distributed, and infused for all patients. Overall time from donor centers to recipient centers was under 60 hours in all cases. Median time to neutrophil engraftment was 13 days. Rates of grade ≥ 3 acute GVHD in the first 180 days and moderate to severe chronic GVHD through 1 year were low at 4% and 5%, respectively. NRM was infrequent at 4% through 1 year. Orca-T exhibited GVHD-free relapse-free survival (GRFS) of 71% & OS of 90% at 1 year. No formal comparison to CIBMTR cohort was performed.

CONCLUSIONS:

Results from patients treated with Orca-T, a high-precision Treg-engineered donor product, suggest a reduction in cGVHD, improved GRFS, and low toxicity relative to historic data. A multicenter randomized-control phase 3 trial comparing Orca-T to SOC is enrolling.

Experimental hematology & oncology

Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting

Letter

Author: Xu, Yang ; Wu, Depei ; Chen, Yiyin

Abstract:

This review summarizes the significant advancements in prophylaxis against graft-versus-host disease (GvHD) presented at the 2022 ASH Annual Meeting. The use of innovative agents and regimens, along with the conventional prophylactic approach of combining post-transplant cyclophosphamide and anti-thymocyte globulin, were discussed. The innovative agents and regimens highlighted in this review include abatacept, the first FDA-approved drug for acute GvHD prophylaxis; RGI-2001, which promotes the expansion of regulatory T cells; and cell therapies such as Orca-T and Orca-Q. These advancements provide promising strategies and options for GvHD prevention, offering hope for improved post-transplant patient outcomes in terms of survival rates.

News (Medical) associated with Orca-T (Orca Bio)

03 Nov 2025

·www.businesswire.com

Orca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 67th American Society of Hematology Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced that new clinical data will be presented in three oral and three poster sessions at the American Society of Hematology (ASH) Annual Meeting from December 6-9 in Orlando, FL. The presentations will span its pipeline of investigational allogeneic T-cell immunotherapies for the treatment of multiple hematological malignancies including Orca-T, Orca-Q and the Orca-T and allogeneic CAR-T combination therapy, OrCAR-T. “Our ongoing clinical evaluation of our pipeline across diverse patient populations, conditioning regimens and donor types underscores our commitment to advancing care for people with blood cancer,” said Nate Fernhoff, Ph.D., co-founder and chief executive officer of Orca Bio. “We look forward to presenting new and expanded evidence from the pivotal Phase 3 study of our lead T-cell immunotherapy, Orca-T, along with data highlighting the potential of our next-generation candidate, Orca-Q, to enable treatment without GvHD prophylaxis. Overall, these findings mark meaningful progress toward our goal of delivering our high-precision approach to more patients who may benefit.” The ASH abstracts are now available at www.hematology.org. Details of the Orca Bio oral and poster presentations follow: Oral Session: 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications Title: Allogeneic HSC and Regulatory T cell (Orca-T) Engineered Cell Therapy Following Reduced Intensity Conditioning: Results of a Single Center Phase 1 Study Abstract Number: 111 Date and Time: December 6, 2025 at 10:00 AM EST Location: OCCC - Chapin Theater (320) Oral Session: 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant Title: Superior Efficacy and Persistence of Orca-T-Allogeneic CAR19/22 Versus Autologous CAR19/22 in High-Risk Adult B-ALL Abstract Number: 514 Date and Time: December 7, 2025 at 10:15 AM EST Location: OCCC - Chapin Theater (320) Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: GVHD Prevention: Post-transplant cyclophosphamide and beyond Title: Preliminary Safety and Efficacy of Myeloablative Orca-Q with Tacrolimus or without GVHD Prophylaxis for Treatment of Advanced Hematologic Malignancies Abstract Number: 932 Date and Time: December 8, 2025 at 3:00 PM EST Location: OCCC - W331 Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I Title: Orca-T Improves cGVHD-free Survival in Patients with a Broad Range of Demographic and Clinical Variables: Results of Randomized, Phase 3 Trial Abstract Number: 2477 Date and Time: December 6, 2025 at 5:30 PM - 7:30 PM EST Location: OCCC - West Halls B3-B4 Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster I Title: Orca-T Demonstrates Favorable Quality of Life and Healthcare Resource Use Compared to Standard AlloHSCT plus Tac/MTX for GVHD Prevention in a Randomized Phase 3 Clinical Trial (Precision-T) Abstract Number: 2473 Date and Time: December 6, 2025 at 5:30 PM - 7:30 PM EST Location: OCCC - West Halls B3-B4 Poster Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD and Immune Reconstitution: Poster III Title: Observational Comparison of Orca-T to Registry-Based Post-Transplant Cyclophosphamide Patients using Matched Unrelated Donor Abstract Number: 6029 Date and Time: December 8, 2025 at 6:00 PM - 8:00 PM EST Location: OCCC - West Halls B3-B4 About Orca-T Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated for the treatment of multiple hematologic malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for the prevention of graft versus host disease or death in patients eligible for hematopoietic stem cell transplant from the U.S. Food and Drug Administration (FDA). The Biologics License Application (BLA) for Orca-T is currently under Priority Review with the FDA with a PDUFA target action date of April 6, 2026. About Orca-Q Orca-Q is Orca Bio’s second-generation investigational allogeneic T-cell immunotherapy under evaluation in clinical trials for the treatment of multiple hematologic malignancies, including in patients with haploidentical and mismatched donors. Orca-Q is a proprietary composition of stem cells combined with specific T-cell subsets derived from healthy donors and engineered by Orca Bio’s high-precision platform. About Orca Bio Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell precision to create personalized cell therapy products intended to replace a patient’s diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what’s possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit www.orcabio.com. Trademarks or registered trademarks used in this press release are the property of their respective owners.

Cell TherapyImmunotherapyPhase 3ASHClinical Result

28 Oct 2025

·www.fiercebiotech.com

AbbVie, Regeneron and Sanofi help fund $80M series A round for Tregs specialist Zag Bio

\"When others in the autoimmune space are zigging, we are zagging,\" CEO Jason Cole said of Zag Bio\'s new approach to developing regulatory T-cell therapies. Zag has come out of stealth with an $80 million series A investment round.\n With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the help of backing from pharma giants AbbVie, Regeneron and Sanofi.The trio are part of an $80 million series A financing round, led by T1D Fund and Polaris Partners, which founded and incubated the Cambridge, Massachusetts, startup.Zag Bio is part of the industry’s rush to develop regulatory T-cell therapies, also known as Tregs. Zag is setting itself apart, however, with its unique thymus-targeting platform.\"The name Zag Bio shows that we are intentionally moving in a new direction to treat autoimmunity by targeting the natural mechanisms in the thymus,\" new CEO Jason Cole told Fierce Biotech. \"When others in the autoimmune space are zigging, we are zagging.\"Cole was most recently the CEO at gene coding specialist SalioGen Therapeutics. He formerly was the chief business officer and chief strategy and financial officer at bluebird bio.\"Despite its integral role in central immune tolerance, the thymus has been inaccessible to drugs of all types.” Cole added in a release.With its platform, Zag believes it can develop antibodies that deliver antigens to restore central immune tolerance in patients with a variety of autoimmune diseases, including Type 1 diabetes. Zag has a candidate in that indication it hopes to move into phase 1 next year.In the thymus, the antigens engage the body’s natural mechanism for T-cell tolerance, Zag explained, expanding antigen-specific Tregs while depleting antigen-specific T effector cells (Teff). The thymic Tregs then migrate to diseased tissues to protect them. Thymic Tregs are epigenetically hardwired, Zag added, to be stable and durable, enabling them to reset the immune system.“Zag Bio is trailblazing an unprecedented therapeutic pathway for medicines to target the thymus, and this positions the company to be an innovator in autoimmune disease treatment,” Alan Crane, a partner at Polaris and co-founder and chairman of Zag Bio, said in a release.Early this month, three pioneering immunologists were awarded the 2025 Nobel Prize in Physiology or Medicine for their work on Tregs. One of the winners was Japanese scientist Shimon Sakaguchi, M.D., Ph.D., who discovered Tregs in 1995 as the “peacekeepers” of the immune system, protecting against an array of autoimmune disorders.Three decades later, no therapies are on the market, but it’s just a matter of time as more than 200 clinical trials are underway harnessing Tregs. Orca Bio is furthest along with a Tregs therapy, facing an FDA decision in April for its blood disease candidate Orca-T. Zag Bio was built on findings in the research lab of Harvard immunology professor and company co-founder Diane Mathis, Ph.D. Other co-founders are Chief Scientific Officer John Kulman, Ph.D., and biotech exec and entrepreneur Jo Viney, Ph.D.Other companies providing financing aside from the three biopharma heavies are Mission BioCapital, Lightspeed Ventures, KdT Ventures, Boxer Capital and Pear VC. While the Nobel Prize brought high-profile attention to Tregs, many big companies have been angling to get a piece of the action. In a similar financing arrangement nearly a year ago, Eli Lilly, Johnson & Johnson and Pfizer invested in South San Francisco-based TRex Bio’s $84 million series B round.Two years ago, AstraZeneca partnered with Quell Therapeutics, paying $85 million to collaborate on Tregs candidates, including one for Type 1 diabetes.

06 Oct 2025

·orcabio.com

Orca Bio Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Orca-T® to Treat Hematological Malignancies

FDA assigns PDUFA target action date of April 6, 2026 If approved, Orca-T would be the first allogeneic T-cell immunotherapy for the treatment of hematological malignancies including acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndromes MENLO PARK, CA, October 6, 2025 – Orca Bio, a late-stage biotechnology company committed to transforming the lives of patients through high-precision cell therapy, today announced the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) seeking approval for Orca-T, its lead investigational allogeneic T-cell immunotherapy, for the treatment of hematological malignancies including acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndromes (MDS). The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of April 6, 2026. "A stem cell transplant has been the only potentially curative option for many people with AML, ALL or MDS, however treatment-related toxicities too often hinder patient recovery. Acceptance of the Orca-T BLA marks a pivotal moment in our ability to deliver a first-in-class therapy designed to improve survival free from complications like graft versus host disease,” said Nate Fernhoff, Ph.D., co-founder and chief executive officer at Orca Bio. “Supported by positive Phase 3 clinical data, today’s regulatory milestone reflects important recognition of the transformative potential of Orca-T. We look forward to working collaboratively with the FDA on the review of our application with the goal of advancing Orca-T and making it available to patients in need.” The BLA submission for Orca-T is supported by positive results from the pivotal Phase 3 study, Precision-T (NCT04013685), a randomized, open-label multi-center study that evaluated the safety, efficacy and tolerability of Orca-T compared to conventional allogeneic hematopoietic stem cell transplant (alloHSCT) in patients with AML, ALL and MDS. The study met its primary endpoint of a statistically significant improvement in survival free of moderate-to-severe chronic graft versus host disease (cGvHD) with Orca-T versus alloHSCT. Orca-T is an investigational allogeneic T-cell immunotherapy being evaluated for the treatment of multiple hematological malignancies including acute leukemias and myelodysplastic syndromes. Orca-T is composed of highly purified regulatory T-cells, hematopoietic stem cells and conventional T-cells derived from peripheral blood from either related or unrelated matched donors. Orca-T has received Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug Designation for the prevention of graft versus host disease or death in patients eligible for hematopoietic stem cell transplant from the U.S. Food and Drug Administration. Orca Bio is a late-stage biotechnology company developing high-precision cell therapies for the treatment of blood cancer and autoimmune diseases. The company’s manufacturing platform uses single-cell precision to create proprietary, uniquely-defined products designed to replace a patient’s diseased blood and immune system with a healthy one. At Orca Bio, we are on a mission to redefine what’s possible for patients by transforming the field of curative allogeneic cell therapy. For more information, visit www.orcabio.com. Trademarks or registered trademarks used in this press release are the property of their respective owners. Corporate Communications Kelsey Grossman media@orcabio.com Investor Relations Joshua Murray ir@orcabio.com

ImmunotherapyCell TherapyPhase 3Priority ReviewClinical Result

100 Deals associated with Orca-T (Orca Bio)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	NDA/BLA	United States	Orca Biosystems, Inc.	06 Oct 2025
Acute Myeloid Leukemia	NDA/BLA	United States	Orca Biosystems, Inc.	06 Oct 2025
Myelodysplastic Syndromes	NDA/BLA	United States	Orca Biosystems, Inc.	06 Oct 2025
Mixed phenotype acute leukemia	Phase 3	United States	Orca Biosystems, Inc.	21 Jun 2022
Secondary Myelodysplastic Syndrome	Phase 3	United States	Orca Biosystems, Inc.	21 Jun 2022
High Risk Myelodysplastic Syndrome	Phase 3	United States	Orca Biosystems, Inc.	-
Myelofibrosis	Phase 2	United States	Orca Biosystems, Inc.	-
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	Phase 1	United States	Stanford University	18 Aug 2022
Blast Phase Chronic Granulocytic Leukemia	Phase 1	United States	Orca Biosystems, Inc.	21 Nov 2019
Blastic Plasmacytoid Dendritic Cell Neoplasm	Phase 1	United States	Orca Biosystems, Inc.	21 Nov 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05316701 (Precision-T \| AML-643 \| Orca-T, CTgov)	Phase 3	Acute Myeloid Leukemia \| Secondary Myelodysplastic Syndrome \| Acute Lymphoblastic Leukemia ... View more	187	Orca-T	hlnnzabhsj = dswlznrbqd setgaxwflg (yqpjueowki, ixwvkbzwpo - ijlbmzdvtc) View more	-	26 Sep 2025
NCT05316701 (Precision-T, PipelineReview) Manual	Phase 3	Acute Myeloid Leukemia \| Acute Lymphoblastic Leukemia \| Hematologic Neoplasms ... View more	187	Orca-T	xdsiypzjjo(afvrrshmug) = jgxrlktqyo ljayepyxry (dtgzzcwcyk, 65 - 87) Met View more	Positive	18 Mar 2025
NCT05316701 (Precision-T, PipelineReview) Manual	Phase 3		187	Allogeneic Stem Cell Transplant	xdsiypzjjo(afvrrshmug) = xippouvnvo ljayepyxry (dtgzzcwcyk, 26 - 51) Met View more	Positive	18 Mar 2025
NCT04013685 (AML-521, SOHO2024)	Phase 1	Acute Myeloid Leukemia	37	Orca-T	rfeypctcbs(hyhfjuiacy) = No occurrence of cytokine release syndrome was reported kmlesajnfa (swtkcnurhd ) View more	Positive	04 Sep 2024
NCT04013685 (ASCO2024)	Phase 1	Acute Myeloid Leukemia First line	37	Orca-T	scvvakpnbw(ohybqxcqko) = acapkrmfkx dyjjtphvui (ivfieuoqbq ) View more	Positive	24 May 2024
NCT04013685 (Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 1	Hematopoietic stem cell transplantation	-	Orca-T	rgpzcqmptw(xlztuepemr) = xxpouingiy mzwfbukrin (iyjsmlppgm ) View more	Positive	01 Feb 2024
NCT04013685 (Tandem Meetings ASTCT and CIBMTR2024) Manual	Phase 1	Hematopoietic stem cell transplantation	-	Post-transplant cyclophosphamide (PTCy)	rgpzcqmptw(xlztuepemr) = fzxjudpdxf mzwfbukrin (iyjsmlppgm ) View more	Positive	01 Feb 2024
NCT04013685 (Tandem Meetings ASTCT and CIBMTR2024)	Phase 1	Hematologic Neoplasms	-	Orca-T	emugipkuqy(arndzvlzgt) = yuuedsrmww skkaiursjd (xoenofrgfg ) View more	-	01 Feb 2024
NCT04013685 (Tandem Meetings ASTCT and CIBMTR2024)	Phase 1	Hematologic Neoplasms	-	Orca-T (Standard of care)	emugipkuqy(arndzvlzgt) = kgfpfjjdwk skkaiursjd (xoenofrgfg ) View more	-	01 Feb 2024
PipelineReview Manual	Phase 1	Acute Myeloid Leukemia \| Acute Lymphoblastic Leukemia \| Philadelphia chromosome positive chronic myelogenous leukemia ... View more	64	Orca-T+BFT (18-54 years of age)	briaamsrum(pnhzpwznyp) = ejgwihyevm xwpjxqxlan (wdgxkcdequ ) View more	Positive	10 Dec 2023
PipelineReview Manual	Phase 1		64	Orca-T+BFT (55 years of age and older)	briaamsrum(pnhzpwznyp) = xalxrywlfg xwpjxqxlan (wdgxkcdequ ) View more	Positive	10 Dec 2023
ASH2023 Manual	Phase 1	Hematologic Neoplasms	15	Orca-T	wyuxonlnwk(aoykkhjysj) = none olqnqltfck (iucfcxdork )	Positive	10 Dec 2023
ASH2023 Manual	Phase 1	High Risk Myelodysplastic Syndrome	16	Orca-T	eqkhmfxfgv(utjtddpasw) = ybftmkrxnt radlfubrlz (sgeybildww ) View more	Positive	09 Dec 2023
Phase 1b single-arm trial (ASH2023)	Phase 1	Hematologic Neoplasms	-	Orca-T	abddaemwzw(szwwdoaxuy) = zorvqqzdso faneuaqdpu (vkqusuorod ) View more	-	09 Dec 2023

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis